The 10 most recent market catalysts affecting $IMRN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 75
Immuron Engages LifeSci Capital as Exclusive Financial Advisor for Strategic Review
Immuron Limited announced it has engaged LifeSci Capital to conduct a strategic review, exploring options such as mergers, acquisitions, or licensing to enhance shareholder value. …
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 75
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation reported a net loss of $24.2 million for Q3 2026, a significant increase from $15.0 million in the prior year, indicating higher operational costs or lower …
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 65
Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo
Immuron announced the publication of its Phase 2 clinical trial data for Travelan in 'Scientific Reports'. This is significant because it provides peer-reviewed scientific validati…
Sep 4, 2026
Macro/Central Bank
Bearish
Impact 75
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
The core event is the robust US jobs report for August, showing 162,000 new jobs, far surpassing the 56,000 estimate. This indicates a strengthening labor market, which is generall…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 85
Immuron Stock Surges Friday: What's Driving the Action?
Immuron Limited announced an exclusive distribution agreement with Calmino group AB to introduce PROIBS, a European-certified medical device for gut health, into the U.S. market. T…
Sep 4, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Friday's Pre-Market Session
This filing highlights the volatile nature of certain healthcare stocks, particularly those with smaller market capitalizations, in pre-market trading. The significant percentage c…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 75
Market-Moving News for September 4th
Immuron (IMRN) secured an exclusive U.S. distribution agreement for Calmino Group's PROIBS, a digestive health product. This is a significant corporate catalyst as it immediately e…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 75
Immuron shares are trading higher after the company announced an exclusive US distribution agreement for PROIBS with Calmino group.
This headline represents a significant corporate catalyst for Immuron. The exclusive US distribution agreement with Calmino Group for PROIBS is a positive development, as it provid…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 65
Immuron Announces Exclusive U.S. Distribution Agreement For Calmino Group's Digestive Health Product PROIBS
The exclusive U.S. distribution agreement for PROIBS is a positive development for Immuron, as it expands their product portfolio and market presence in the lucrative U.S. digestiv…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 65
Immuron Sees Prelim FY2026 Sales $5.462M
Immuron disclosed preliminary sales guidance for fiscal year 2026, projecting $5.462 million. This is a forward-looking statement, providing an early indication of the company's ex…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.